Compare Simon Property Group Inc (SPG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Simon Property Group Inc vs BIO-TECHNE Corp — how do they compare? Simon Property Group Inc trades at $219.28 (market cap $71.52B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Simon Property Group Inc is far larger — about 6.4× BIO-TECHNE Corp's market cap, and Simon Property Group Inc pays the higher dividend (3.99%). Which is the better fit depends on your goals.
| SPG | TECH | |
|---|---|---|
Market Cap | $71.52B | $11.24B |
Sector | Real Estate | Health |
52-Week High | $236.70 | $72.29 |
52-Week Low | $165.20 | $43.31 |
Enterprise Value | $100.00B | $11.32B |
Dividend Yield | 3.99% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Simon Property Group (SPG) trades at $222.91, up 0.49% on the day, near its consensus price target of $223.50. The stock shows strong fundamentals with a P/E of 15.5 and robust profitability, including a net income margin of 70.59% and ROE of 127.05%. Recent Q2 2026 earnings beat expectations with FFO of $3.29 per share, driven by leasing momentum and raised guidance. Technical indicators are bearish overall, with support at $221 and resistance at $224. The company maintains a solid dividend, paying $2.25 in H1 2026.
Outlook: SPG benefits from strong operational performance and raised 2026 guidance, supported by tenant demand and property NOI growth. Investment opportunities include consistent earnings beats and a high ROE. Risks involve elevated long-term debt of $24.21 billion, potential interest rate pressures, and e-commerce competition. Analyst sentiment is mixed with 40.54% buy ratings, but technical bearish signals suggest near-term caution.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
